S
Sylvain Choquet
Researcher at Pierre-and-Marie-Curie University
Publications - 195
Citations - 5611
Sylvain Choquet is an academic researcher from Pierre-and-Marie-Curie University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 35, co-authored 149 publications receiving 4371 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
Sylvain Choquet,Véronique Leblond,Raoul Herbrecht,Gérard Socié,Anne-Marie Stoppa,Peter Vandenberghe,Alain Fischer,Franck Morschhauser,Gilles Salles,Walter Feremans,Etienne Vilmer,Marie-Noëlle Peraldi,Philippe Lang,Yvon Lebranchu,Eric Oksenhendler,Jeanne Luce Garnier,Thierry Lamy,Arnaud Jaccard,Augustin Ferrant,Fritz Offner,Olivier Hermine,Anne Moreau,Samira Fafi-Kremer,Patrice Morand,Lucienne Chatenoud,Nathalie Berriot-Varoqueaux,Loïc Bergougnoux,Noel Milpied +27 more
TL;DR: It is concluded that rituximab is effective and safe in PTLD, with stable responses at 1 year, and the response rate and overall survival might be improved by combining ritUXimab with other treatments.
Journal ArticleDOI
Post-transplant lymphoproliferative disorders
Vikas R. Dharnidharka,Angela C Webster,Olivia M. Martinez,Jutta K. Preiksaitis,Véronique Leblond,Sylvain Choquet +5 more
TL;DR: Post-transplant lymphoproliferative disorders are a group of conditions that involve uncontrolled proliferation of lymphoid cells as a consequence of extrinsic immunosuppression after organ or haematopoietic stem cell transplant.
Journal ArticleDOI
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Ulrich Trappe,Stephan Oertel,Véronique Leblond,Peter Mollee,Monica Sender,Petra Reinke,Ruth Neuhaus,Hans B. Lehmkuhl,Heinz A. Horst,Gilles Salles,Franck Morschhauser,Arnaud Jaccard,Thierry Lamy,Malte Leithäuser,Heiner Zimmermann,Ioannis Anagnostopoulos,Martine Raphael,Hanno Riess,Sylvain Choquet +18 more
TL;DR: The results support the use of sequential immunochemotherapy with rituximab and CHOP in PTLD and help to avoid the toxic effects of CHOP on patients with post-transplantation lymphoproliferative disorder.
Journal ArticleDOI
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Carole Soussain,Khê Hoang-Xuan,Luc Taillandier,Emmanuelle Fourme,Sylvain Choquet,Francis Witz,Olivier Casasnovas,Brigitte Dupriez,Bertrand Souleau,Anne Laure Taksin,Christian Gisselbrecht,Arnaud Jaccard,Antonio Omuro,Marc Sanson,Maud Janvier,Brigitte Kolb,Jean Marc Zini,Véronique Leblond +17 more
TL;DR: IC + HCR is an effective treatment for refractory and recurrent PCNSL and all but one of the 27 patients who underwent IC + H CR entered complete remission.
Journal ArticleDOI
Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders
Véronique Leblond,Nathalie Dhedin,Marie-France Mamzer Bruneel,Sylvain Choquet,Olivier Hermine,Raphaël Porcher,Stephanie Nguyen Quoc,Frederic Davi,Frédéric Charlotte,Richard Dorent,Benoit Barrou,Jean-Paul Vernant,Martine Raphael,Vincent Levy +13 more
TL;DR: The IPI failed to identify a patient subgroup with better survival and was less predictive of the response rate than was a specific index using two risk factors (PS and number of involved sites), which defined three groups of patients: low- risk patients whose median survival time has not yet been reached, intermediate-risk patients with a median survivalTime of 34 months, and high-risk Patients with a Median survival time of 1 month.